adam17

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer.

KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).

GW280264X (Carbamic acid) is an inhibitor of ADAM17 .

ADAM17-IN-1 is a selective ADAM17 inhibitor. It functions by reducing dendritic cell (DC) metabolic activity through ADAM17 inhibition, thereby impairing DC antigen presentation, suppressing allergen-specific Th2 cell polarization, and decreasing the secretion of Th2 cytokines (IL-4, IL-5, IL-13). In mouse models of house dust mite (HDM)-induced type 2/eosinophilic airway inflammation, ADAM17-IN-1 demonstrates protective effects. This compound can be utilized in research on type 2 hyperreactive allergic asthma.

IK-862 is a selective inhibitor of TACE (ADAM17).

TAPI-1, an ADAM17/TACE inhibitor, inhibits shedding of cytokine receptors.

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.

ADAMTS7-IN-1 (Compound 3a) serves as a potent and selective ADAMTS7 inhibitor, exhibiting a K i value of 9 nM. It is primarily utilized in atherosclerosis research.

BMS-561392 Formic acid (BMS-561392 formate) is a small molecule inhibitor, the formate salt form of BMS-561392. As a selective TACE inhibitor and ADAM17 blocker, this compound reduces TNFα levels and is primarily used for research on inflammation-related diseases such as inflammatory bowel disease.

(S,S)-TAPI-1, an isomer of TAPI-1, is a metalloproteinase (MMP) inhibitor and a TACE (ADAM17) inhibitor known for its potent inhibition of various cell surface protein shedding.

ZSNI-21 is a dual inhibitor targeting ADAM17 and HDAC2. It effectively suppresses the proliferation of Bel-7402 cells and exhibits significant anti-metastatic properties against HCC-LM3 cells, making it a promising candidate for hepatocellular carcinoma (HCC) research.

Ro 32-7315 is a selective inhibitor of ADAM17.

Aderbasib (INCB007839) is an orally active and potent ADAM10 and ADAM17 inhibitor with antitumor activity, used for studying cancer and cardiovascular diseases.

TAPI-1 is an ADAM17/TACE inhibitor, which blocks shedding of cytokine receptors.

TAPI1 acetate is a salt form of TAPI1. TAPI1 (TNF-α processing inhibitor-1) is a TACE (ADAM17) inhibitor that inhibits shedding of TNF-α, TNFRI (p60), and TNFRII (p80), IL-6 other cytokine receptors; TAPI-1 is also a metalloproteinase MMP inhibitor that promotes cisplatin-induced ESCC cell apoptosis by inhibiting the NF-κB signaling pathway to promote cisplatin-induced apoptosis in ESCC cells.

BMS-561392 formate, the formate derivative of BMS-561392, functions as a TNF alpha-converting enzyme (TACE) inhibitor and an ADAM17 blocker. It is utilized in the research of inflammatory bowel disease [1] [2].

Anti-TMEFF2 Antibody represents a highly specialized monoclonal antibody specifically engineered to target the human TMEFF2 protein (Tomoregulin-1) with exceptional binding affinity. It effectively facilitates the measurable detection of TMEFF2-positive malignant cells across various preclinical experimental models to evaluate the delivery of cytotoxic payloads like Auristatin E (MMAE) during strictly monitored laboratory observation periods and molecular investigations to evaluate the disruption of prostate cancer progression.